摘要
目的观察草酸铂（L-OHP）联合诺维苯（NVB）治疗原发性腹膜癌的临床疗效及毒副反应。方法2002年8月至2006年3月采用草酸铂联合诺维苯治疗原发性腹膜癌7例，L-OHP 130mg／m^2，第1天；NVB25mg／m^2，第1、8天，4周为一周期，至少化疗3周期，中位化疗周期为3周期（2～6周期）。结果CR1例，PR3例，NC 1例，PD2例，总有效率57．1％。生存时间3．7～31个月，中位生存期21．1个月。主要不良反应为骨髓抑制、末梢神经炎及静脉炎。白细胞下降和血小板下降率分别为57．1％和14．2％，末梢神经炎及静脉炎发生率分别为28．5％和57．1％。结论草酸铂联合诺维苯是治疗原发性腹膜癌的有效方法，毒副反应基本可耐受，可作为一线化疗方案的补充。
Objective To evaluate the efficacy and toxic side effects of vinorelbine combined with oxaliplatin in treatment of primary peritoneal carcinoma（PPC）. Methods From Aug. 2002 to March 2006,7 cases of PPC were treated with vinorelbine and oxaliplatin ： vinorelbine 25 mg/m^2 , days 1 and 8, oxaliplatin 135 mg/m^2 , VD, day 1. Every 4 weeks constituted a cycle. All patients received at least 3 cycles. The median of chemotherapy cycles was 3 （2-6 cycles）. Results The total response rate was 57.1% （4/7）, including CR 1 and PR 3. The median survival time was 21.1 months. The main toxic reactions were myelosupression, peripheral neuritis and phlebitis, Ⅲ-Ⅳ-grade neutropenia occurring in 57. 1% （4/7）, peripheral neuritis 28.5% （2/7） and phlebitis 57.1% （4/7）. Conclusion Vinorelbine combined with oxaliplatin was a safe and effective therapy for patients with PPC. The toxic side effects were tolerable. It can be used as an alternative of first-line chemotherapy.
出处
《中国肿瘤临床与康复》
2007年第5期465-467,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
腹膜肿瘤/药物疗法
草酸铂
诺维苯
Peritoneal neoplasms/drug therapy
Oxaliplatin
Vinorelbine
